Page 1

Table of Contents ( Mark One ) ☐ ☑ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington , D.C. 20549 FORM 20 - F REGISTRATION STATEMENT PURSUANT TO SECTION 12 ( b ) OR ( g ) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ANNUAL REPORT PURSUANT TO SECTION 13 OR 15 ( d ) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31 , 2020 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 ( d ) OF THE SECURITIES EXCHANGE ACT □ OF1934 For the transition period from to OR □ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15 ( d ) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of event requiring this shell company report Commission file number : 001-39950 Evaxion Biotech A / S ( Exact name of Registrant as specified in its charter ) The Kingdom of Denmark ( Jurisdiction of incorporation or organization ) Dr. Neergaards Vej 5f DK - 2970 Hoersholm , Denmark ( Address of principal executive offices ) Lars Staal Wegner , MD Chief Executive Officer Evaxion Biotech A / S Dr. Neergaards Vej 5f DK - 2970 Hoersholm Denmark Tel : +45 53 53 18 50 ( Name , Telephone , E - mail and / or Facsimile number and Address of Company Contact Person ) Securities registered or to be registered pursuant to Section 12 ( b ) of the Act : Title of each class American Depositary Shares , each representing one ordinary share , nominal value DKK 1 per Trading Symbol share EVAX Ordinary Shares , nominal value of DKK 1 per share * Name of each exchange on which registered The Nasdaq Stock Market LLC The Nasdaq Stock Market LLC * Not for trading , but only in connection with the registration of American Depositary Shares representing such Ordinary shares pursuant to requirements of the U.S. Securities and Exchange Commission . Securities registered or to be registered pursuant to Section 12 ( g ) of the Act : None Securities for which there is a reporting obligation pursuant to Section 15 ( d ) of the Act :